Avant Diagnostics, Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by VOLLMERS ALVARO, was filed 10 May 2010.
Avant Diagnostics, Inc: what insiders have been doing
This page follows insider dealings at Avant Diagnostics, Inc as filed with SEC (Form 4). Nothing new has been filed by managers of Avant Diagnostics, Inc in twelve months, the latest record being from 26 September 2017.
Looking back to 2010, when coverage begins, insiders filed 1 purchase and 2 sales.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2017FY ended September 2017 · cache
- 1,000,000 shares@ US$0.016850.1% of flowCommon StockSEC:0001639365-17-000007:0
- 1,000,000 shares@ US$0.016849.9% of flowCommon StockSEC:0001639365-17-000007:1
- 1,400,000 shares0Common Stock, $0.00001 par valueSEC:0001144204-10-030424:0
- 1,550,000 sharesCommon Stock, $0.00001 par valueSEC:0001144204-10-025884:0Canonical exit: 2 Aug 2010 (T+90)
4 of 4 declarations
About Avant Diagnostics, Inc
Avant Diagnostics, Inc is a company focused on developing diagnostic tests for cancer. It is listed on the XNAS market.
